ZA936629B - Potentiation of immunogenic response - Google Patents

Potentiation of immunogenic response

Info

Publication number
ZA936629B
ZA936629B ZA936629A ZA936629A ZA936629B ZA 936629 B ZA936629 B ZA 936629B ZA 936629 A ZA936629 A ZA 936629A ZA 936629 A ZA936629 A ZA 936629A ZA 936629 B ZA936629 B ZA 936629B
Authority
ZA
South Africa
Prior art keywords
antigen
immunogen
forms
potentiation
immune response
Prior art date
Application number
ZA936629A
Other languages
English (en)
Inventor
Robert S Becker
Karen Biscardi
Laura Ferguson
Lorne Erdile
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25479200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA936629(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of ZA936629B publication Critical patent/ZA936629B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Jib Cranes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Radar Systems Or Details Thereof (AREA)
ZA936629A 1992-09-14 1993-09-08 Potentiation of immunogenic response ZA936629B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94317392A 1992-09-14 1992-09-14

Publications (1)

Publication Number Publication Date
ZA936629B true ZA936629B (en) 1994-03-30

Family

ID=25479200

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA936629A ZA936629B (en) 1992-09-14 1993-09-08 Potentiation of immunogenic response

Country Status (15)

Country Link
US (4) US5662909A (de)
EP (1) EP0588578B2 (de)
JP (1) JP2512689B2 (de)
AT (1) ATE187338T1 (de)
AU (1) AU677592B2 (de)
CA (1) CA2105629A1 (de)
DE (1) DE69327214T3 (de)
DK (1) DK0588578T4 (de)
ES (1) ES2141750T5 (de)
FI (1) FI110234B (de)
GR (1) GR3032543T3 (de)
IL (2) IL106968A (de)
NO (1) NO313178B1 (de)
PT (1) PT588578E (de)
ZA (1) ZA936629B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US20050106137A1 (en) * 2000-05-05 2005-05-19 Stephen Grimes Chimeric peptide immunogens
DE122011100043I1 (de) * 2000-12-27 2011-12-15 Gilead Sciences Inc Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.
EP2280074A3 (de) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
EP1411770A4 (de) * 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US6814729B2 (en) 2002-06-27 2004-11-09 Technovision Gmbh Laser vision correction apparatus and control method
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4946676A (en) * 1986-08-27 1990-08-07 De Staat Der Nederlanden Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
EP0270295A3 (de) * 1986-12-03 1989-08-02 Connaught Laboratories Limited Konjugat-Impfstoff
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao

Also Published As

Publication number Publication date
FI934013L (fi) 1994-03-15
NO313178B1 (no) 2002-08-26
ES2141750T3 (es) 2000-04-01
GR3032543T3 (en) 2000-05-31
DK0588578T3 (da) 2000-03-27
JPH06192125A (ja) 1994-07-12
EP0588578B1 (de) 1999-12-08
FI110234B (fi) 2002-12-31
US5853736A (en) 1998-12-29
DE69327214T2 (de) 2000-09-07
EP0588578B2 (de) 2005-04-13
US5662909A (en) 1997-09-02
JP2512689B2 (ja) 1996-07-03
EP0588578A1 (de) 1994-03-23
NO933261D0 (no) 1993-09-13
FI934013A0 (fi) 1993-09-14
ES2141750T5 (es) 2005-12-01
US6024963A (en) 2000-02-15
DK0588578T4 (da) 2005-07-25
ATE187338T1 (de) 1999-12-15
AU677592B2 (en) 1997-05-01
CA2105629A1 (en) 1994-03-15
PT588578E (pt) 2000-05-31
IL106968A (en) 1999-10-28
NO933261L (no) 1994-03-15
AU4622693A (en) 1994-03-24
US5837264A (en) 1998-11-17
DE69327214D1 (de) 2000-01-13
IL106968A0 (en) 1993-12-28
DE69327214T3 (de) 2005-12-01
IL130075A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
IL106968A0 (en) Potentiation of immunogenic response
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ATE410183T1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
EP1170016A3 (de) Impfstoff auf Urease-Basis gegen Helicobacter Infektionen
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
BR9814487A (pt) "vacina"
AU2001295673A1 (en) Vaccine composition
ES2179105T3 (es) Adyuvantes proteinicos.
DE60130569D1 (de) Verpackung von replikon-partikeln eines positiv-strängigen rna-virus
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
PT792165E (pt) Composicoes imunogenicas
WO1999056772A3 (en) Hepatitis vaccine
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
BR0013574A (pt) Antìgeno vacina de moraxella
WO2003007986A8 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
IL100765A0 (en) Vaccine composition against influenza,with synergic effects containing influenza virus core as an additive
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
KR940701272A (ko) 감독된 복귀 돌연변이체 혈청형1 마렉병 백신